EVOLUS INC (EOLS) Stock Price, Quote, News and Summary
NASDAQ:EOLS - Nasdaq - US30052C1071 - Common Stock
EOLS Quote and Key Statistics
EVOLUS INC
NASDAQ:EOLS (1/21/2025, 8:00:02 PM)
After market: 13.94 +0.46 (+3.41%)13.48
+2.97 (+28.26%)
EOLS Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.15% | ||
| ROE | -941.6% | ||
| Debt/Equity | 20.58 |
EOLS Performance and Technical Analysis
EOLS Ownership and Analysts
EOLS Latest News and Analysis
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
The company expects to soon expand from a single-product player to a "multi-product innovator."
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
About EOLS
Company Profile
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 322 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Company Info
EVOLUS INC
520 Newport Center Dr Ste 1200
Newport Beach CALIFORNIA 92660 US
CEO: David Moatazedi
Employees: 304
Company Website: https://www.evolus.com
Investor Relations: http://investors.evolus.com
Phone: 19492844555
EOLS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.56 | 359.88B | ||
| JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
| MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.37 | 199.39B | ||
| PFE | PFIZER INC | 10.33 | 150.97B | ||
| SNY | SANOFI-ADR | 12.49 | 129.60B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
| ZTS | ZOETIS INC | 29.09 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.3 | 68.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B |